Title: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Journal: European journal of cancer (Oxford, England : 1990) 20121101
Title: A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Journal: Pediatric blood & cancer 20121101
Title: Trabectedin has promising antineoplastic activity in high-grade meningioma.
Journal: Cancer 20121015
Title: Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Journal: Investigational new drugs 20121001
Title: Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Journal: European journal of cancer (Oxford, England : 1990) 20121001
Title: Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Journal: Gynecologic oncology 20121001
Title: Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Journal: Medical oncology (Northwood, London, England) 20120901
Title: Role of palliative chemotherapy in advanced epithelioid sarcoma.
Journal: American journal of clinical oncology 20120801
Title: Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
Journal: Current opinion in pharmacology 20120801
Title: Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Journal: International journal of cancer 20120701
Title: TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
Journal: Anticancer research 20120701
Title: A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Journal: Investigational new drugs 20120601
Title: Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Journal: Lung cancer (Amsterdam, Netherlands) 20120601
Title: A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120501
Title: Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.
Journal: Biochemical pharmacology 20120501
Title: Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
Journal: Investigational new drugs 20120401
Title: Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
Journal: Investigational new drugs 20120401
Title: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120301
Title: Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120301
Title: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Journal: European journal of cancer (Oxford, England : 1990) 20120301
Title: PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
Journal: The Journal of clinical investigation 20120301
Title: Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.
Journal: Cancer chemotherapy and pharmacology 20120201
Title: Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Journal: Clinical and experimental immunology 20120201
Title: A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Journal: Gynecologic oncology 20120101
Title: Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.
Journal: Expert opinion on drug metabolism & toxicology 20120101
Title: Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option.
Journal: Onkologie 20120101
Title: A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Journal: PloS one 20120101
Title: Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Journal: Current pharmaceutical design 20120101
Title: Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.
Journal: Onkologie 20120101
Title: Trabectedin in advanced soft tissue sarcoma: case series.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20120101
Title: Activity of trabectidin in desmoplastic small round cell tumor.
Journal: Medical oncology (Northwood, London, England) 20111201
Title: Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Journal: Gynecologic oncology 20111201
Title: Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.
Journal: ACS chemical biology 20111118
Title: Systemic management strategies for metastatic soft tissue sarcoma.
Journal: Drugs 20111112
Title: Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Journal: Cancer chemotherapy and pharmacology 20111101
Title: Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
Journal: Cancer chemotherapy and pharmacology 20111101
Title: Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Journal: Gynecologic oncology 20110901
Title: XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.
Journal: Chemistry & biology 20110826
Title: ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Journal: Cancer 20110801
Title: Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
Journal: Gynecologic oncology 20110801
Title: Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Journal: Molecular cancer therapeutics 20110801
Title: The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110701
Title: Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
Journal: European journal of pharmacology 20110511
Title: Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.
Journal: Gynecologic oncology 20110501
Title: Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Journal: European journal of cancer (Oxford, England : 1990) 20110501
Title: Introduction. Trabectedin treatment in GYN cancers.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501
Title: Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501
Title: An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501
Title: Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501
Title: Trabectedin for the treatment of relapsed ovarian cancer.
Journal: Health technology assessment (Winchester, England) 20110501
Title: Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110401
Title: Trabectedin and ovarian cancer: statistical trickery.
Journal: Prescrire international 20110401
Title: Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Journal: Gynecologic oncology 20110301
Title: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Journal: Neoplasia (New York, N.Y.) 20110201
Title: Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Title: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Title: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Title: Trabectedin in ovarian cancer: could we expect more?
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Title: Mestastatic gastric cancer from malignant fibrous histiocytoma.
Journal: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20110101
Title: Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
Journal: Acta haematologica 20110101
Title: Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
Journal: Tumori 20110101
Title: Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
Journal: Tumori 20110101
Title: [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Journal: Revue medicale de Liege 20110101
Title: [Trabectedin registry].
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101
Title: Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20101201
Title: Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101015
Title: Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
Journal: Anti-cancer drugs 20100901
Title: Recent synthetic approaches to 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20100823
Title: Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
Journal: Investigational new drugs 20100801
Title: A review of trabectedin (ET-743): a unique mechanism of action.
Journal: Molecular cancer therapeutics 20100801
Title: Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100715
Title: Trabectedin therapy for sarcomas.
Journal: Current opinion in oncology 20100701
Title: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701
Title: Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701
Title: [Current impact of natural products in the discovery of anticancer drugs].
Journal: Annales pharmaceutiques francaises 20100701
Title: Characterization and analysis of human chordoma cell lines.
Journal: Spine 20100601
Title: [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Journal: Bulletin du cancer 20100601
Title: Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Journal: Pharmacogenomics 20100601
Title: Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Journal: Expert review of anticancer therapy 20100601
Title: Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100501
Title: Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Journal: Health technology assessment (Winchester, England) 20100501
Title: Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Journal: Investigational new drugs 20100401
Title: [A rare tumour with a distinctive histological appearance].
Journal: Annales de pathologie 20100401
Title: Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Journal: Cancer research 20100315
Title: Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Journal: Cleveland Clinic journal of medicine 20100301
Title: Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Journal: Drugs 20100212
Title: Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Journal: Anti-cancer drugs 20100101
Title: Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?
Journal: Hepato-gastroenterology 20100101
Title: Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Journal: Marine drugs 20100101
Title: Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101
Title: Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20091101
Title: Trabectedin: an anticancer drug from the sea.
Journal: Expert opinion on pharmacotherapy 20091101
Title: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901
Title: [Recommendations for diagnostic and therapeutic management of soft tissue sarcoma].
Journal: Bulletin du cancer 20090901
Title: Trabectedin.
Journal: British journal of clinical pharmacology 20090901
Title: The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Journal: Marine drugs 20090901
Title: Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20090801
Title: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20090801
Title: Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
Journal: Gynecologic oncology 20090801
Title: Trabectedin.
Journal: The oncologist 20090801
Title: Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Journal: Prescrire international 20090801
Title: Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.
Journal: Biochemical pharmacology 20090715
Title: Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
Journal: Molecular cancer therapeutics 20090701
Title: Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Journal: Molecular cancer therapeutics 20090701
Title: Trabectedin for the management of soft-tissue sarcoma.
Journal: Expert review of anticancer therapy 20090601
Title: Marine natural products.
Journal: Clinical advances in hematology & oncology : H&O 20090601
Title: Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Journal: Drugs of today (Barcelona, Spain : 1998) 20090601
Title: Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090515
Title: In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.
Journal: Biochemical pharmacology 20090515
Title: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Journal: Cancer chemotherapy and pharmacology 20090501
Title: Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20090501
Title: Ready for a comeback of natural products in oncology.
Journal: Biochemical pharmacology 20090501
Title: Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Journal: Natural product reports 20090301
Title: Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Journal: Molecular cancer therapeutics 20090201
Title: Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090201
Title: Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Journal: Current clinical pharmacology 20090101
Title: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Journal: Current medicinal chemistry 20090101
Title: ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
Journal: PloS one 20090101
Title: Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis.
Journal: The Journal of organic chemistry 20081219
Title: Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20081201
Title: Structure elucidation and 1H/13C NMR spectral assignments of four trabectedin related compounds.
Journal: Magnetic resonance in chemistry : MRC 20081201
Title: Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081015
Title: Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081015
Title: A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20081001
Title: In vitro radiosensitisation by trabectedin in human cancer cell lines.
Journal: European journal of cancer (Oxford, England : 1990) 20080801
Title: Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Journal: Cancer chemotherapy and pharmacology 20080601
Title: Chemotherapeutic management of soft tissue sarcoma.
Journal: The Surgical clinics of North America 20080601
Title: Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Journal: Expert opinion on pharmacotherapy 20080601
Title: Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
Journal: Molecular cancer therapeutics 20080501
Title: [Advance of several types of important marine antitumor drugs].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20080501
Title: Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity.
Journal: Toxicology and applied pharmacology 20080401
Title: Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Journal: Seminars in oncology 20080401
Title: Role of homologous recombination in trabectedin-induced DNA damage.
Journal: European journal of cancer (Oxford, England : 1990) 20080301
Title: Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Journal: Journal of natural products 20080301
Title: Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Journal: Clinical pharmacology and therapeutics 20080101
Title: Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
Journal: Molecular cancer therapeutics 20080101
Title: A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Journal: British journal of cancer 20071217
Title: Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Journal: Cell proliferation 20071201
Title: Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20071001
Title: Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Journal: Future oncology (London, England) 20070801
Title: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Journal: The Lancet. Oncology 20070701
Title: Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
Journal: Cancer biology & therapy 20070701
Title: Trabectedin--a targeted chemotherapy?
Journal: The Lancet. Oncology 20070701
Title: Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Journal: Cancer chemotherapy and pharmacology 20070501
Title: Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Journal: Clinical colorectal cancer 20070501
Title: Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Journal: Investigational new drugs 20070201
Title: Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Journal: Journal of cellular biochemistry 20070201
Title: New therapeutics for soft-tissue sarcomas in adults.
Journal: Oncology (Williston Park, N.Y.) 20070101
Title: Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Journal: Clinical pharmacokinetics 20070101
Title: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Journal: Drugs 20070101
Title: Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
Journal: Journal of medicinal chemistry 20061116
Title: Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Journal: Gynecologic oncology 20060901
Title: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Journal: Cancer research 20060815
Title: Synthetic studies on Et-743. Asymmetric, stereocontrolled construction of the tetrahydroisoquinoline core via radical cyclization on a glyoxalimine.
Journal: Organic letters 20060720
Title: Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates.
Journal: Bioorganic & medicinal chemistry letters 20060715
Title: ET-743: a novel agent with activity in soft-tissue sarcomas.
Journal: Current opinion in oncology 20060701
Title: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Journal: European journal of cancer (Oxford, England : 1990) 20060701
Title: A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Journal: British journal of cancer 20060605
Title: Scientists are searching the seas for cancer drugs.
Journal: Journal of the National Cancer Institute 20060517
Title: ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.
Journal: Natural product research 20060510
Title: Stereospecific formal total synthesis of ecteinascidin 743.
Journal: Angewandte Chemie (International ed. in English) 20060303
Title: Total synthesis of ecteinascidin 743.
Journal: Journal of the American Chemical Society 20060111
Title: In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.
Journal: Investigational new drugs 20060101
Title: [News of the year 2005 in sarcomas].
Journal: Bulletin du cancer 20060101
Title: Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Journal: Drugs in R&D 20060101
Title: Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Journal: Reviews on recent clinical trials 20060101
Title: DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.
Journal: Molecular pharmacology 20051201
Title: The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
Journal: International journal of oncology 20051201
Title: Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters.
Journal: Molecular pharmacology 20051101
Title: DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
Journal: Chemistry & biology 20051101
Title: New agents and new formulations for the treatment of ovarian cancer.
Journal: Clinical advances in hematology & oncology : H&O 20051101
Title: Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Journal: Investigational new drugs 20051001
Title: In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Journal: Anti-cancer drugs 20051001
Title: Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Journal: Anti-cancer drugs 20050901
Title: Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820
Title: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820
Title: Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.
Journal: Biochemical pharmacology 20050701
Title: RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
Journal: European journal of cancer (Oxford, England : 1990) 20050701
Title: Synthetic studies toward ecteinascidin 743.
Journal: The Journal of organic chemistry 20050527
Title: Hepatotoxicity and metabolism of trabectedin: a literature review.
Journal: Pharmacological research 20050501
Title: Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Journal: Molecular cancer therapeutics 20050501
Title: Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Journal: Cancer research 20050401
Title: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320
Title: Marine natural products as anticancer drugs.
Journal: Molecular cancer therapeutics 20050201
Title: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120
Title: A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050115
Title: Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Journal: European journal of cancer (Oxford, England : 1990) 20050101
Title: ET-743: a novel agent with activity in soft tissue sarcomas.
Journal: The oncologist 20050101
Title: SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743.
Journal: Biochemistry 20041109
Title: New drugs from the sea.
Journal: Journal of chemotherapy (Florence, Italy) 20041101
Title: Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
Journal: International journal of cancer 20041010
Title: [Progress in the studies on antitumor natural product ecteinascidin-743].
Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20040801
Title: A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20040601
Title: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415
Title: Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro.
Journal: Cancer chemotherapy and pharmacology 20040401
Title: Progress in the clinical development of new marine-derived anticancer compounds.
Journal: Anti-cancer drugs 20040401
Title: Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.
Journal: Journal of mass spectrometry : JMS 20040401
Title: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301
Title: Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Journal: Cancer chemotherapy and pharmacology 20040101
Title: The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Journal: Oncology research 20040101
Title: Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations.
Journal: Biochemical pharmacology 20031215
Title: In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
Journal: British journal of cancer 20031215
Title: New therapeutic strategies for soft tissue sarcomas.
Journal: Current treatment options in oncology 20031201
Title: Progress in the development and acquisition of anticancer agents from marine sources.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20031101
Title: Preclinical and clinical results with the natural marine product ET-743.
Journal: Expert opinion on investigational drugs 20031101
Title: In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Journal: Experimental hematology 20031101
Title: Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.
Journal: The Journal of biological chemistry 20031010
Title: Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Journal: Cancer research 20030915
Title: Rationale for drug combinations.
Journal: European journal of cancer (Oxford, England : 1990) 20030901
Title: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20030901
Title: The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
Journal: European journal of cancer (Oxford, England : 1990) 20030901
Title: Orphan anticancer drug rejected.
Journal: The Lancet. Oncology 20030901
Title: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Journal: Cancer 20030815
Title: Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Journal: Cancer chemotherapy and pharmacology 20030801
Title: Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Journal: Anti-cancer drugs 20030801
Title: Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030701
Title: Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics.
Journal: Biomolecular engineering 20030701
Title: Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
Journal: Organic letters 20030612
Title: [Development of marine-derived anti-cancer compounds].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20030501
Title: The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
Journal: Acta crystallographica. Section C, Crystal structure communications 20030401
Title: Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.
Journal: Molecular pharmacology 20030301
Title: Pregnane X receptor-dependent and -independent effects of 2-acetylaminofluorene on cytochrome P450 3A23 expression and liver cell proliferation.
Journal: Biochemical and biophysical research communications 20030110
Title: Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Journal: Drugs in R&D 20030101
Title: [Perspectives on the oncologist pharmacopoeia].
Journal: Bulletin du cancer 20030101
Title: Ecteinascidin-743.
Journal: Clinical journal of oncology nursing 20030101
Title: Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20030101
Title: Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Journal: Expert opinion on investigational drugs 20021201
Title: Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Journal: Cancer research 20021201
Title: Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Journal: Molecular cancer therapeutics 20021201
Title: Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.
Journal: The Journal of biological chemistry 20021101
Title: Sea squirt assaults sarcomas.
Journal: The Lancet. Oncology 20021101
Title: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Journal: Cancer chemotherapy and pharmacology 20021001
Title: Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020901
Title: Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat.
Journal: Cancer research 20020801
Title: Editorial comment on 'In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results' by Albella and colleagues.
Journal: European journal of cancer (Oxford, England : 1990) 20020701
Title: In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Journal: European journal of cancer (Oxford, England : 1990) 20020701
Title: Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Journal: Anti-cancer drugs 20020701
Title: Ecteinascidin-743 inhibits activated but not constitutive transcription.
Journal: Cancer research 20020615
Title: Total synthesis of ecteinascidin 743.
Journal: Journal of the American Chemical Society 20020612
Title: Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity.
Journal: Chemistry & biology 20020501
Title: Safety and efficacy of ET-743: the French experience.
Journal: Anti-cancer drugs 20020501
Title: A clinical armamentarium of marine-derived anti-cancer compounds.
Journal: Anti-cancer drugs 20020501
Title: ET-743: more than an innovative mechanism of action.
Journal: Anti-cancer drugs 20020501
Title: ET-743: the US experience in sarcomas of soft tissues.
Journal: Anti-cancer drugs 20020501
Title: Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Journal: Anti-cancer drugs 20020401
Title: A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.
Journal: Journal of medicinal chemistry 20020214
Title: Studies directed to the total synthesis of ET 743 and analogues thereof: an expeditious route to the ABFGH subunit.
Journal: Organic letters 20020110
Title: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020101
Title: ET-743.
Journal: Drugs 20020101
Title: Unique features of the mode of action of ET-743.
Journal: The oncologist 20020101
Title: Cytotoxic agents in the era of molecular targets and genomics.
Journal: The oncologist 20020101
Title: A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Journal: The oncologist 20020101
Title: Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Journal: Chemistry & biology 20011201
Title: A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Journal: Cancer chemotherapy and pharmacology 20011201
Title: The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Journal: Chemistry & biology 20011101
Title: ET-743 (PharmaMar/NCI/Ortho Biotech).
Journal: Current opinion in investigational drugs (London, England : 2000) 20011101
Title: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20011001
Title: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010901
Title: [High-dose chemotherapy in soft tissue sarcomas of adults].
Journal: Bulletin du cancer 20010901
Title: Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Journal: Anti-cancer drugs 20010901
Title: Anticancer squirt.
Journal: Nature medicine 20010801
Title: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
Journal: Nature medicine 20010801
Title: Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
Journal: Journal of the American Chemical Society 20010711
Title: Transcription of the multidrug resistance gene MDR1: a therapeutic target.
Journal: Molecular interventions 20010601
Title: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Journal: International journal of cancer 20010515
Title: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.
Journal: Nature medicine 20010501
Title: Okadaic acid induces transcription of junB through a CCAAT box and NF-Y.
Journal: Gene 20010404
Title: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301
Title: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301
Title: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010201
Title: Science and serendipity in cancer research.
Journal: European journal of cancer (Oxford, England : 1990) 20010101
Title: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Journal: European journal of cancer (Oxford, England : 1990) 20010101
Title: Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010101
Title: The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
Journal: Advances in experimental medicine and biology 20010101
